(Total Views: 392)
Posted On: 11/03/2022 2:37:43 PM
Post# of 154867
Cyrus Arman, "I believe the shareholders interest are appropriately represented by the current BOD....our pooled data with the relapsed Refractory TNBC population showed promising survival data that we plan to follow-up on.
"I am thrilled to be here...we already have an FTD for mTNBC and we believe that Leronlimab has the potential to become the SOC for these indications in the future."
NASH TAM 200 billion.
2.3 Million women are diagnosed with mTNBC each year...with 685,000 fatalities as a result...prognosis is poor...let's get at it.
Incidentally...Hope S. Rugo receives research support for clinical trials through the Univ. of Calif, Pfizer, Merck, Novartis, Lilly, Roche, Odonate,Diiachi, Seattle Genetics, Macrogenix, Sermonix, AstraZeneca, OBI, Gilead, and Ayala...also has a consultancy/Honoraria with SAMSUNG.
Thanks for the transcript MGK_2
"I am thrilled to be here...we already have an FTD for mTNBC and we believe that Leronlimab has the potential to become the SOC for these indications in the future."
NASH TAM 200 billion.
2.3 Million women are diagnosed with mTNBC each year...with 685,000 fatalities as a result...prognosis is poor...let's get at it.
Incidentally...Hope S. Rugo receives research support for clinical trials through the Univ. of Calif, Pfizer, Merck, Novartis, Lilly, Roche, Odonate,Diiachi, Seattle Genetics, Macrogenix, Sermonix, AstraZeneca, OBI, Gilead, and Ayala...also has a consultancy/Honoraria with SAMSUNG.
Thanks for the transcript MGK_2
(4)
(0)
